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Summary The aim of this multicentric, retrospective, and uncontrolled studywas to
evaluate the efficacy and safety of levetiracetam (LEV) in 81 children younger than 4
years with refractory epilepsy. At an average follow-up period of 9 months, LEV
administration was found to be effective in 30% of patients (responders showing more
than a 50% decrease in seizure frequency) of whom 10 (12%) became seizure free. This
efficacy was observed for focal (46%) as well as for generalized seizures (42%). In
addition, in a group of 48 patients, we compared the initial efficacy (evaluated at an
average of 3months of follow-up) and the retention at amean of 12months of LEV, with
regard to loss of efficacy (defined as the return to the baseline seizure frequency).
Twenty-two patients (46%) were initial responders. After a minimum of 12 months of
follow-up,9of48patients (19%)maintained the improvement, 4 (8%)ofwhomremained
seizure free. A loss of efficacy was observed in 13 of the initial responders (59%).
Maintained LEV efficacy was noted in patients with focal epilepsy and West syndrome.
LEV was well tolerated. Adverse events were seen in 18 (34%) patients. The main side
effects were drowsiness and nervousness. Adverse events were either tolerable or
resolved in time with dosage reduction or discontinuation of the drug.
We conclude that LEV is safe and effective for a wide range of epileptic seizures and
epilepsy syndromes and, therefore, represents a valid therapeutic option in infants and
young children affected by epilepsy.
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Levetiracetam (LEV) is one of the latest antiepilep-
tic drug (AED) available on the market.1,2 Mechan-
isms underlying its antiepileptic activity are
partially understood. LEV partially inhibits N-type
high-voltage-activated Ca2+ currents and reduces
the Ca2+ release from intraneuronal stores.3 LEV is
also able to reverse the effects of negative allosteric
modulators of g-aminobutyric acid (GABA) and gly-
cine-gated currents.4 LEV has a favorable pharma-
cokinetic profile characterized by rapid and almost
complete absorption after oral administration, lin-
ear pharmacokinetics, minimal protein binding,
predominantly renal excretion, and no significant
drug interactions.2,5 In children the pharmacoki-
netics resulted to be similar to that observed in
adults, even though clearance is approximately
30—40% higher.5 Although double blind placebo-con-
trolled clinical trials demonstrated the efficacy of
LEV in both adults6,7 and children,8 safety and effi-
cacy of LEV in infancy remain to be ascertained.
Here we report on a retrospective, multicenter
study which has been conducted in order to acquire
further information about efficacy and tolerability
of LEV in a pediatric population under four years of
age affected by several types of seizures and epi-
lepsy syndromes.Patients and methods
Data were obtained from records of patients treated
with LEV for epilepsy from January 2003 to June
2005. Data for an open, multicentered, retrospec-
tive study of children treated with LEV were col-
lected from six pediatric neurology departments in
Italy. Patients were selected by the following cri-
teria: (i) aged less than 4 years; (ii) exhibiting at
least four seizures a month during the 3 months
before LEV was administered. Patients with progres-
sive neurological disorders were excluded from the
study. Family and personal histories were taken and
neurological examinations performed on all
patients. Details of sex, age, anti-epilepsy drug
(AED) usage before LEV therapy, concomitant ther-
apy, and duration of treatments and of epilepsy
were collected. All patients underwent brain mag-
netic resonance imaging (MRI). Biochemical ana-
lyses, chromosomal investigations, and screening
for metabolic disorders were carried out in all
patients. Seizure types and epilepsy syndromes
were classified in accordance with the International
League against Epilepsy (ILAE) classifications, and
the recently proposed diagnostic scheme for
patients with seizures and epilepsy.9—11Patients
A total of 81 children (36 girls and 45 boys) aged less
than 4 years were recruited. Neuromotor retarda-
tion was observed in 60 (74%) patients and it was
considered to be severe in 27, moderate in 15, and
mild in 18. Mean seizure frequency was 42 seizures
per month (range 16—162). Themean age to the first
seizure was nine months (range 1 month—3.5 years),
and mean duration of the epileptic history was 17
months (range 3—41 months). Epilepsy was sympto-
matic in 41 (50%) patients, probably symptomatic in
32 (40%), and idiopathic in 8 (10%). Focal seizures
were observed in 44 (54%) patients, and generalized
seizures in 57 (70%). In 17 (21%) patients, partial
seizures evolved to secondary generalization.
Twenty-four (30%) patients exhibited more than
one type of seizure. Informed consent for LEV
administration was obtained from the parents.
The mean number of AEDs tried before starting
LEV treatment was four (range 1—10). The number
of AEDs administered when LEV treatment was
started ranged from one to three (average two).
Drugs administered at the outset of LEV therapy
included valproate (41%), phenobarbital (31%), car-
bamazepine (27%), vigabatrin (26%), topiramate
(22%), clonazepam (20%), lamotrigine (9%), oxcar-
bazepine (7%), chlormethyldiazepam (6%), and
ACTH (10%).
Levetiracetam was administered in two equal
daily doses of 5—10 mg/kg. The dose was increased
every week up to a maximum of 62 mg/kg per day. In
the event of an adverse reaction, the titration phase
was prolonged based on the clinical condition. Dur-
ing treatment complete peripheral blood counts,
urinary analysis, determinations of blood creatinine
level and alanine and aspartate aminotransferase
levels were taken.
Response
In comparison with baseline seizure frequency and
severity, the response to LEV treatment was classi-
fied as follows: complete cessation (100% seizure
control); very good (decrease in seizure frequency
by 50—99%); minimal (21—50% seizure reduction
with minimal change in seizure severity); unmodi-
fied (less than 20% seizure reduction) or worsening
(increase seizure frequency to >50%). Physicians
openly reported adverse events related to the drug
administration.
LEV retention at 12 months
In a group of 48 patients, the initial LEV efficacy,
defined as the number of responsive patients at a
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months), was compared with the retention at 12
months (range 12—14) of LEV, to examine the loss of
efficacy. Retention at 12 months of LEV, a composite
measure of efficacy and adverse events in clinical
practice, was defined as the percentage of patients
still taking LEVafter a minimum period of 12 months
of follow-up (range 12—45 months). Loss of efficacy
was defined as the return to the baseline seizure
frequency.Figure 1 Efficacy of LEV on different seizure types
(more than one type of seizures could be present in a
single patient). FS: focal seizures; SGTC: secondary gen-
eralized tonic seizures; GTCS: generalized tonic—clonic
seizures; IS: Infantile spasms; MS: myoclonic seizures; AA:
atypical absences; TS: tonic seizures; AS: atonic seizures.Results
The mean age of patients at the time of initial LEV
treatment was 27 months (range 2—46 months). The
mean duration of treatment was 9.2 months (range
3—42 months). Mean LEV daily dose was 41 mg/kg
(range 25—62 mg/kg per day).
Efficacy
At their last visit, 37 (46%) patients out of 81 were
still being treated with LEV, whereas LEV had been
stopped in the remaining 44 (54%) patients. Twenty-
four (30%) patients were considered to be respon-
ders because they showed a reduction in their sei-
zure frequency by more than 50%. Specifically, 10
(12%) children became seizure free, 14 (17%)
showed a seizure reduction of more than 50%, and
18 (22%) showed seizure reduction of 20—50%. In 24
(30%) patients seizure frequency remained
unchanged and in a further 15 (18%) patients sei-
zures increased more than 50% in comparison with
the baseline. In 13 (16%) nonresponders LEV was
maintained because either seizures were reduced in
severity or there were positive psychotropic effects.
Seizure reduction was seen over a wide range of
seizure types (Fig. 1) and epilepsy syndromesTable 1 Efficacy of LEV according to epilepsy syndromes
Epilepsy syndromes No. of
Focal epilepsy 30
Probably symptomatic (12)
Symptomatic (18)
West syndrome 17
Cryptogenic (7)
Symptomatic (10)
Lennox—Gastaut 2
Myoclonic-astatic 2
Eyelid myoclonia 2
Dravet’s syndrome 3
Early myoclonic encephalopathy 6
Unclassifiable 19(Table 1). LEVappeared to be effective in both focal
(46% of responders) and generalized epilepsy (42% of
responders). Efficacy was also observed in three
(12%) patients presenting with an unclassifiable type
of epilepsy syndrome. In eight (10%) patients, the
good initial response was lost within 4 weeks with
seizure frequency returning to a pretreatment
level.
In two patients, one affected by focal epilepsy
and one with West syndrome, LEV monotherapy was
successful because both remained responders at the
last follow-up visit. In a further six (7%) children,
one or more concomitant drugs was reduced without
affecting seizure frequency.
LEV retention at 12 months
The group of 48 patients was not different from the
remaining patients in terms of age, sex, epilepsy
history, seizure frequency, and number of antiepi-
leptic drugs administered (Wilcoxon sum rank test).patients 81 Responders/seizure free
11/6
(7/4)
(4/2)
6/3
(4/2)
(2/1)
0/0
2/1
1/0
1/0
0/0
3 (0)
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Table 2 LEVefficacy according to epilepsy syndromes after a mean follow-up period of 3 and 12 months, respectively
Epilepsy syndromes No. of
patients 48
After a
mean of 3
month (R/SF)
After a
mean of 12
month (R/SF)
Loss of
efficacy (%)
Focal epilepsy 18 9/5 5/2 44%
Probably symptomatic (11) (6/3) (4/2) (33%)
Symptomatic (7) (3/2) (1/0) (67%)
West syndrome 10 5/2 3/1 40%
Cryptogenic (5) (3/2) (2/1) (33%)
Symptomatic (5) (2/0) (1/0) (50%)
Lennox—Gastaut 2 2/0 0/0 100%
Myoclonic-astatic 2 2/1 1/1 50%
Dravet’s syndrome 2 2/0 0/0 100%
Early myoclonic encephalopathy 2 0/0 0/0 —
Unclassifiable 7 2/0 0/0 100%
R: responders; SF: seizure free.Efficacy retention at 12 months was observed in nine
out of 48 patients (19%), of whom four (8%)
remained seizure free (Table 2). Five of these
patients (56%) were affected by focal epilepsy,
three (33%) by West syndrome, and one (11%) by
myoclonic-astatic epilepsy. A loss of efficacy was
seen in thirteen (59%) of the 22 initial responders.
With respect to epilepsy syndromes, efficacy loss
was less obvious in patients with focal epilepsy (44%)
and West syndrome (40%) (Table 2).
Safety
At least one adverse event was seen in 28 (34%)
patients. The most common adverse events were
drowsiness (45%), nervousness (36%), cognitive dis-
turbances (29%), loss of appetite (14%), and sleep
disturbances (7%). One patient (4%) presented with
vomiting. Eight patients showed more than one side
effect. No life threatening side effects were
observed during the study and all side effects were
either tolerable or resolved in time through dosage
reduction or discontinuation of the drug. There
were no significant laboratory anomalies in liver
function, renal function, or hematology.
Discussion
Controlled and open-label studies showed the effi-
cacy of LEV in a wide range of seizures and epilepsies
in children and adults.6—8,12—18 In a study designed
to evaluate short-term efficacy and tolerability of
LEV, Glauser et al.8 found that giving LEV to children
with partial seizures led to a statistically greater
reduction in partial seizures, with 44.6% of children
responsive to LEV showing more than a 50% drop in
seizures with seven (6.9%) becoming seizure free.Prospective, open-label studies showed that LEV
effectively improves seizure control as an add-on
drug for resistant epilepsy in childhood.19,20 Opp
et al.19 noted that 24.9% of 209 children were
responders, with more than 50% of seizure reduction
during LEV therapy. In a previous study, we observed
higher responder rates after a mean follow-up per-
iod of 7 months, LEV being effective in 39% of
children, with 8% of patients becoming seizure
free.20 Similar findings were observed by Lagae
et al.21 in a study of 67 children. These authors
noted that 90% of children placed under LEV alone
were responders. Seizure frequency before and
after 12 months of LEV therapy was also evaluated
in 59 children affected by intractable epilepsy.22
The authors found that the response rate at 12
months was 52%, with 22% of patients being seizure
free. Lower responder rates (29%) were observed by
Koukkari et al.21 in a retrospective study that
included 52 children with refractory epilepsy.
LEV is currently approved in Italy for the treat-
ment of patients older than 4 years of age with
partial seizures and secondary generalized epilepsy.
We believe this study is the first evaluation of the
efficacy and safety of LEV in infants aged less than 4
years with epileptic seizures and epileptic syn-
dromes. In an open-label, prospective study we
previously reported that LEV was effective in con-
trolling epilepsy in 16 infants in whom a higher
responder rate was observed compared with rates
seen in older children.20 Moreover, a number of
young children were treated with LEV and reported
in other studies.19—24 However, systematic data are
not yet available. The design of the present study
reflects daily clinical practice. Although this intro-
duces some methodological weaknesses, it provides
a more natural and realistic view of the use of LEV in
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were refractory to first line drugs. The main aim of
add-on treatment in these patients was to improve
their quality of life by decreasing seizure frequency
as much as possible and by limiting adverse events,
rather than to make them seizure free.24
LEV efficacy was evaluated in relation to seizure
types and to epilepsy syndromes. Thirty percent of
patients had a more than a 50% reduction in seizure
frequency after amean follow-up period of 9months.
The percentage of responders was lower than that
reported in older children in previous studies.20,21—23
The lower response rates we observed may be
because of insufficient experience with LEV in young
children, resulting in a very strong selection bias for
infants with very difficult-to-treat epilepsies. This
bias is further enhanced in our data which are con-
stituted by pooled data of the first experiences with
LEV coming from six pediatric neurology depart-
ments. Although the patients we investigated did
not have long histories of epilepsy, up to 10 AEDs
had been used before LEV therapywas started. More-
over, the majority of children were mentally
retarded, with epilepsy beingmainly related to brain
injuries or brain malformations. As in the previous
studies involving older children, LEV resulted to
effective in both focal epilepsy (46% of responders)
and generalized epilepsy (42% of responders). In
particular, good responseswerealso found inpatients
with West syndrome with six of 17 of such patients
(35%) being classified as responders. This is a good
result considering that the majority of patients
exhibited refractive infantile spasms. Of course,
further clinical trials are needed to determine the
efficacy of LEV in these epilepsy syndromes. In fact,
the size of our population was not so large to enable
us to draw more definite conclusions.
We compared the efficacy in 48 patients observed
after a mean of three months of follow-up with
retention after 12 months of LEV, with regard to
loss of efficacy. According to Krakow et al.25 the
retention rate is an important measure of the effi-
cacy and adverse events of the drug because it is a
reliable indicator over time. Nineteen percent of
our patients were still responsive to LEV after a
minimum of 12 months of follow-up. Loss of efficacy
was observed in 59% of the initial responders.
Although our series was small, a well-sustained
LEV efficacy was observed in patients with focal
epilepsy. Since comedication was not (or only
slightly) altered before seizure relapse, we suggest
that the loss of efficacy with LEV was likely related
to the development of tolerance to the drug.
The mean dose of LEV in our study, 41 mg/kg per
day, was similar to that used in studies on older
children.20,21,23 As clearance of LEV in young chil-dren is 30—40% greater,5 it is possible that better
results could be obtained with higher doses of LEV.
However, previous studies did not find a relationship
between LEV doses and efficacy.2,20 Moreover, we
found significantly higher doses in nonresponder
patients than in responder patients (data not
shown).
LEV has been reported to be a well-tolerated,
relatively safe drug.20 Adverse reactions, such as
headache, somnolence, and anorexia, have inci-
dences varying from 30%20,21,23 to 44.9%.19 Acute
psychosis26,27 and choreoathetosis20 have also been
reported. Hemorrhagic colitis lacking infectious
etiology and severe apnea were reported in two
children. In both patients symptoms reversed after
LEV was stopped.19 Side effects appear to be more
frequent with high LEV doses (>40 mg/kg per
day).24 However, recent reports emphasized that
LEV is well tolerated at doses up to 270 mg/kg
per day.22 Drowsiness, aggressiveness, and attention
disorders represent the main side effects in patients
treated with LEV.20,24 Opp et al.19 found that they
were most frequent in children with physical handi-
caps or mental retardation. These authors sug-
gested that this pediatric population should to be
monitored carefully for adverse effects of LEV ther-
apy. In the present study, adverse reactions were
observed in 34% of patients and were usually limited
to the titration period. As in previous reports,20,22
somnolence and irritability were the most common
adverse reactions, occurring in up to 28% of
patients. However, in all patients the side effects
were mild in severity and transient.
We conclude that although further studies of LEV
monotherapy are required, the drug is safe and
effective for a wide range of epilepsies and that
it is a valid therapeutic option in infancy and early
childhood.References
1. Shorvon SD, van Rijckevorsel K. A new antiepileptic drug. J
Neurol Neurosurg Psychiatry 2002;72:426—9.
2. Vigevano F. Levetiracetam in pediatrics. J Child Neurol
2005;20:87—93.
3. Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam
inhibits the high-voltage-activated Ca(2+) current in pyrami-
dal neurones of rat hippocampal slices. Neurosci Lett
2001;306:5—8.
4. Rigo JM, Hans G, Nguyen L, et al. The anti-epileptic drug
levetiracetam reverses the inhibition by negative allosteric
modulators of neuronal GABA- and glycine-gated currents. Br
J Pharmacol 2002;136:659—72.
5. Pellock JM, Glauser TA, Bebin EM, et al. Pharmacokinetic study
of levetiracetam in children. Epilepsia 2001;42:1574—9.
6. Ben-Menachem E, Falter U. Efficacy and tolerability of leve-
tiracetam 3000 mg/d in patients with refractory partial
350 S. Grosso et al.seizures: a multicenter, double-blind, responder-selected
study evaluating monotherapy. European Levetiracetam
Study Group. Epilepsia 2000;41:1276—83.
7. Leppik IE, Biton V, Sander JW, Wieser HG. Levetiracetam and
partial seizure subtypes: pooled data from three randomized,
placebo-controlled trials. Epilepsia 2003;44:1585—7.
8. Glauser TA, Ayala R, Elterman RD, et al. Double-blind pla-
cebo-controlled trial of adjunctive levetiracetam in pediatric
partial seizures. Neurology 2006;66:1654—60.
9. Commission on classification and terminology of the Interna-
tional League Against Epilepsy, 1981. Proposal for revised
clinical and electroencephalographic classification of epilep-
tic seizures. Epilepsia 1981;22:489—501.
10. Commission on classification and terminology of the Interna-
tional League Against Epilepsy, 1989. Proposal for revised
classification of epilepsies and epileptic syndromes. Epilepsia
1989;30:389—99.
11. Engel Jr J International League Against Epilepsy (ILAE). A
proposed diagnostic scheme for people with epileptic sei-
zures and with epilepsy: report of the ILAE Task Force on
Classification and Terminology. Epilepsia 2001;42:796—803.
12. Genton P, Sadzot B, Fejerman N, et al. Levetiracetam in a
broad population of patients with refractory epilepsy:
interim results of the international SKATE trial. Acta Neurol
Scand 2006;113:387—94.
13. Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P. Multi-
center double-blind, randomized, placebo-controlled trial of
levetiracetam as add-on therapy in patients with refractory
partial seizures. European Levetiracetam Study Group. Epi-
lepsia 2000;41:1179—86.
14. Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for
partial seizures: results of a double-blind, randomized clin-
ical trial. Neurology 2000;55:236—42.
15. Glauser TA, Pellock JM, Bebin EM, et al. Efficacy and safety of
levetiracetam in children with partial seizures: an open-label
trial. Epilepsia 2002;43:518—24.16. Herranz JL, Rufo-Campos M, Arteaga R. Effectiveness and
tolerability of levetiracetam in 43 children and adolescents
with epilepsy. Rev Neurol 2003;37:1005—8.
17. Wheless JW, Ng YT. Levetiracetam in refractory pediatric
epilepsy. J Child Neurol 2002;17:413—5.
18. De los Reyes EC, Sharp GB, Hale SE. Levetiracetam in the
treatment of Lennox—Gastaut syndrome. Ann Neurol
2001;50(Suppl. 1):S108.
19. Opp J, Tuxhorn I, May T, et al. Levetiracetam in children with
refractory epilepsy: a multicenter open label study in Ger-
many. Seizure 2005;14:476—84.
20. Grosso S, Franzoni E, Coppola G, et al. Efficacy and safety of
levetiracetam: an add-on trial in children with refractory
epilepsy. Seizure 2005;14:248—53.
21. Lagae L, Buyse G, Ceulemans B. Clinical experience with
levetiracetam in childhood epilepsy: an add-on and mono-
therapy trial. Seizure 2005;14:66—71.
22. Mandelbaum DE, Bunch M, Kugler SL, Venkatasubramanian A,
Wollack JB. Efficacy of levetiracetam at 12 months in chil-
dren classified by seizure type, cognitive status, and previous
anticonvulsant drug use. J Child Neurol 2005;20:590—4.
23. Koukkari MW, Guarino EJ. Retrospective study of the use of
levetiracetam in childhood seizure disorders. J Child Neurol
2004;19:944—7.
24. Lagae L, Buyse G, Deconinck A, Ceulemans B. Effect of
levetiracetam in refractory childhood epilepsy syndromes.
Eur J Paediatr Neurol 2003;7:123—8.
25. Krakow K, Walker M, Otoul C, Sander JW. Long-term con-
tinuation of levetiracetam in patients with refractory epi-
lepsy. Neurology 2001;56:1772—4.
26. Kossoff EH, Bergey GK, Freeman JM, Vining EP. Levetiracetam
psychosis in children with epilepsy. Epilepsia 2001;42:
1611—3.
27. Mula M, Trimble MR, Sander JW. Psychiatric adverse events in
patients with epilepsy and learning disabilities taking leve-
tiracetam. Seizure 2004;13:55—7.
